@article{915e3ce28b7a43febe7ee0e14f513e21,
title = "Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma",
keywords = "Checkpoint inhibitor, Immunotherapy, PD-L1, Pembrolizumab, Tumor mutational burden",
author = "Vineeth Sukrithan and Jason Sandler and Rasim Gucalp and Gralla, {Richard J.} and Bal{\'a}zs Halmos",
note = "Funding Information: B.H. is receiving clinical research support from Merck. The remaining authors have stated that they have no conflicts of interest.",
year = "2019",
month = may,
doi = "10.1016/j.cllc.2018.12.013",
language = "English (US)",
volume = "20",
pages = "e242--e246",
journal = "Clinical lung cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",
}
